Advertisement

Topics

Pro-Trader Daily: Featured Company News - Blueprint Medicines Announced New Data from Ongoing Phase-1 Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors

07:56 EST 14 Nov 2017 | FinanzNachrichten

Research Desk Line-up: Puma Biotechnology Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headl...

Original Article: Pro-Trader Daily: Featured Company News - Blueprint Medicines Announced New Data from Ongoing Phase-1 Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors

NEXT ARTICLE

More From BioPortfolio on "Pro-Trader Daily: Featured Company News - Blueprint Medicines Announced New Data from Ongoing Phase-1 Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...